After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...

Medtronic has received approval from the US Food and Drug Administration (FDA) for BrainSense, its adaptive deep brain stimulation (aDBS) therapy for patients living with Parkinson’s disease. The ...

Medtronic Percept™ DBS therapy is the only sensing-enabled † DBS system available, allowing a physician to use data from a patient’s brain activity to personalize their treatment. Andy says Medtronic ...

DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (MDT) (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's ...

The technology is designed to adjust therapy in real time based on a patient’s brain activity, potentially improving symptom control, according to a Feb. 24 news release from the company. The ...

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease For 30 years, people with Parkinson's disease ...

NEW YORK, April 26 (Reuters) - U.S. drugmaker Eli Lilly and Co and device maker Medtronic Inc said they would test a Parkinson's disease medicine that has intrigued researchers over the past decade ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, 2025 ...

On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...